MA34055B1 - Chlorhydrate d'agomelatine hydrate et sa preparation - Google Patents

Chlorhydrate d'agomelatine hydrate et sa preparation

Info

Publication number
MA34055B1
MA34055B1 MA35192A MA35192A MA34055B1 MA 34055 B1 MA34055 B1 MA 34055B1 MA 35192 A MA35192 A MA 35192A MA 35192 A MA35192 A MA 35192A MA 34055 B1 MA34055 B1 MA 34055B1
Authority
MA
Morocco
Prior art keywords
preparation
agomelatin
agomelatine
hydrate hydrochloride
formula
Prior art date
Application number
MA35192A
Other languages
Arabic (ar)
English (en)
Inventor
Hanbin Shan
Zhedong Yuan
Xueyan Zhu
Peng Zhang
Hongjuan Pan
Xiong Yu
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44599556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34055(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA34055B1 publication Critical patent/MA34055B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Abstract

L'invention porte sur un chlorhydrate d'agomélatine hydraté de formule (i), sur sa préparation, sur son utilisation et sur une composition pharmaceutique le contenant. Ledit chlorhydrate d'agomélatine hydraté obtenu par le présent procédé a une solubilité considérablement accrue par rapport à l'agomélatine et par conséquent est plus approprié pour la fabrication de formulations pharmaceutiques. à l'aide du présent procédé, une pureté élevée peut être obtenue par un procédé simple, dépourvu de toutes étapes compliquées. Dans la formule, x représente cl.
MA35192A 2010-03-17 2011-03-17 Chlorhydrate d'agomelatine hydrate et sa preparation MA34055B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201010126254XA CN102190594A (zh) 2010-03-17 2010-03-17 阿戈美拉汀氯化氢水合物及其制备方法
PCT/CN2011/071910 WO2011113362A1 (fr) 2010-03-17 2011-03-17 Chlorhydrate d'agomélatine hydraté et sa préparation

Publications (1)

Publication Number Publication Date
MA34055B1 true MA34055B1 (fr) 2013-03-05

Family

ID=44599556

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35192A MA34055B1 (fr) 2010-03-17 2011-03-17 Chlorhydrate d'agomelatine hydrate et sa preparation

Country Status (36)

Country Link
US (1) US8729131B2 (fr)
EP (1) EP2547649B1 (fr)
JP (1) JP5634532B2 (fr)
KR (1) KR101406727B1 (fr)
CN (2) CN102190594A (fr)
AP (1) AP2012006492A0 (fr)
AU (1) AU2011229618B2 (fr)
BR (1) BR112012023317B1 (fr)
CA (1) CA2792417C (fr)
CL (1) CL2012002540A1 (fr)
CR (1) CR20120462A (fr)
CU (1) CU20120137A7 (fr)
CY (1) CY1116086T1 (fr)
DK (1) DK2547649T3 (fr)
EA (1) EA022067B1 (fr)
EC (1) ECSP12012155A (fr)
ES (1) ES2530772T3 (fr)
GE (1) GEP20156231B (fr)
GT (1) GT201200259A (fr)
HK (1) HK1177451A1 (fr)
HR (1) HRP20150071T1 (fr)
IL (1) IL221782A (fr)
MA (1) MA34055B1 (fr)
ME (1) ME02054B (fr)
MX (1) MX2012010541A (fr)
NI (1) NI201200140A (fr)
NZ (1) NZ602450A (fr)
PE (1) PE20130013A1 (fr)
PL (1) PL2547649T3 (fr)
PT (1) PT2547649E (fr)
RS (1) RS53815B1 (fr)
SG (1) SG183868A1 (fr)
SI (1) SI2547649T1 (fr)
TN (1) TN2012000435A1 (fr)
UA (1) UA105425C2 (fr)
WO (1) WO2011113362A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2551257A1 (fr) * 2011-07-28 2013-01-30 Laboratorios Del. Dr. Esteve, S.A. Co-cristaux d'agomélatine avec formeurs de co-cristaux
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
KR20150020191A (ko) * 2012-05-14 2015-02-25 상하이 라이트핸드 팜테크 주식회사 아고멜라틴 산기 복합체와 그의 제조방법 및 용도
CN102702041B (zh) * 2012-05-14 2013-08-14 上海右手医药科技开发有限公司 阿戈美拉汀苯磺酸类复合物及其制备方法
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法
CN102718676B (zh) * 2012-06-26 2014-04-09 福建广生堂药业股份有限公司 阿戈美拉汀硫酸盐及其制备方法
WO2014096373A1 (fr) 2012-12-21 2014-06-26 Laboratorios Lesvi, S. L. Procédé de préparation de n-(2-(7-méthoxy-1-naphtalényl)éthyl)acétamide et de formes solides de celui-ci
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2015013865A1 (fr) * 2013-07-29 2015-02-05 Les Laboratoires Servier Complexes d'acides sulfoniques et d'agomélatine et leur préparation
KR101470794B1 (ko) * 2014-06-30 2014-12-08 순천향대학교 산학협력단 아고멜라틴 공결정의 제조 방법 및 이를 포함하는 조성물
EP3613745B1 (fr) 2015-07-02 2021-09-01 Acerta Pharma B.V. Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
US10367757B2 (en) * 2016-08-27 2019-07-30 Nicira, Inc. Extension of network control system into public cloud

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE01991193T1 (de) * 2000-10-30 2004-07-08 Teva Pharmaceutical Industries Ltd. Neue kristall- und solvatformen von ondansetronhydrochlorid und verfahren zu deren herstellung
FR2890562B1 (fr) * 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2934859B1 (fr) 2008-08-05 2010-08-13 Servier Lab Nouveau procede de synthese de l'agomelatine
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
WO2012046253A2 (fr) * 2010-10-08 2012-04-12 Msn Laboratories Limited Procédé de préparation de n-[2- (7-méthoxy-l-naphthyl) éthyl] acétamide et ses nouvelles formes cristallines

Also Published As

Publication number Publication date
ES2530772T3 (es) 2015-03-05
AU2011229618B2 (en) 2014-05-22
DK2547649T3 (en) 2015-03-02
WO2011113362A1 (fr) 2011-09-22
CN102190594A (zh) 2011-09-21
GT201200259A (es) 2013-12-03
BR112012023317B1 (pt) 2021-07-06
CL2012002540A1 (es) 2013-01-11
PE20130013A1 (es) 2013-01-26
NI201200140A (es) 2012-11-09
JP5634532B2 (ja) 2014-12-03
CA2792417A1 (fr) 2011-09-22
KR101406727B1 (ko) 2014-06-13
PL2547649T3 (pl) 2015-04-30
UA105425C2 (ru) 2014-05-12
CN102958911B (zh) 2015-11-25
AP2012006492A0 (en) 2012-10-31
TN2012000435A1 (en) 2014-01-30
BR112012023317A2 (pt) 2016-05-24
SG183868A1 (en) 2012-10-30
SI2547649T1 (sl) 2015-03-31
EA201201294A1 (ru) 2013-04-30
US8729131B2 (en) 2014-05-20
EP2547649B1 (fr) 2014-11-19
GEP20156231B (en) 2015-01-26
EP2547649A4 (fr) 2013-09-04
US20130005820A1 (en) 2013-01-03
CA2792417C (fr) 2015-11-24
ECSP12012155A (es) 2012-12-28
MX2012010541A (es) 2012-10-05
IL221782A (en) 2017-11-30
NZ602450A (en) 2014-12-24
EP2547649A1 (fr) 2013-01-23
JP2013522241A (ja) 2013-06-13
CN102958911A (zh) 2013-03-06
ME02054B (me) 2015-05-20
PT2547649E (pt) 2014-12-29
CU20120137A7 (es) 2012-11-15
HRP20150071T1 (en) 2015-02-27
RS53815B1 (en) 2015-06-30
CY1116086T1 (el) 2017-02-08
HK1177451A1 (zh) 2013-08-23
KR20120128712A (ko) 2012-11-27
EA022067B1 (ru) 2015-10-30
CR20120462A (es) 2012-10-05
AU2011229618A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
MA34055B1 (fr) Chlorhydrate d'agomelatine hydrate et sa preparation
MY160460A (en) Agomelatine hydrochloride hydrate and preparation thereof
EP2536736A4 (fr) Production de 6'-o-sialyllactose et intermédiaires
NO20090328L (no) Nye forbindelser 385
IN2014MN02106A (fr)
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2013001677A (es) Formulaciones estables de linaclotida.
UA115881C2 (uk) Алкоксипіразоли як активатори розчинної гуанілатциклази
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
IN2012DN03182A (fr)
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
IN2014DN00090A (fr)
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
IN2012DN02502A (fr)
MX2013001234A (es) Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
PH12015502429A1 (en) Dicarboxylic acid compound
IN2011KN05169A (fr)
MX2012008413A (es) Composicion novedosa de retigabina.
BR112012024708A2 (pt) composição de compostos orgânicos
IN2013DN02555A (fr)